CSL announces rise in full year net profit
Major strategic initiatives, including demerger, to transform CSL Globalbiotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit (NPATA) was US$3.3 billion, up 14% on a constant currency basis. https://mma.prnewswire.com/media/341673/csl_behring_logo.jpg Dr. Paul McKenzie, CSL's […]